Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Lonza Acquires Controlling Stake in Octane Biotech

By Lonza Group Ltd | October 30, 2018

Lonza has acquired a controlling stake in Octane Biotech, with the right to acquire full ownership. The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing. Octane Orthobiologics Inc. will maintain exclusivity to a certain subset of orthopedic clinical indications for use in the Cocoon system. 

The two companies have been collaborating since 2015 on the development of the Cocoon system, a patient-scale, closed, and automated cell-therapy manufacturing system.

Following an intensive joint-development program, the Cocoon system now incorporates the majority of unit operations needed for scalable end-to-end manufacturing of cell therapies, including Mesenchymal stem cells (MSC) and Chimeric Antigen Receptor T cells (CAR-T cells).

In addition, the flexible, disposable cassettes can be modified to accommodate a wide range of autologous cell therapy processes for adherent cells, non-adherent cells, and combination products. This advantage provides flexibility in a field that utilizes a variety of cell types and processes.

Cocoon also aims to answer some of the key challenges facing autologous cell therapies as they reach the commercial stage, including variability in cell yields and the stringent regulations in place once products are registered. Automating autologous cell therapy manufacturing in a closed system enables superior process control, leading to fewer deviations and higher cell quality.

The Cocoon system is part of Lonza’s array of autologous cell therapy offerings. The company currently is working with a number of customers, with therapies in various clinical stages, to integrate the Cocoon manufacturing equipment as a key part of their clinical and commercial manufacturing strategy.

Octane Biotech’s 24 employees at the current site in Kingston, Ontario, Canada will continue to support activities as the Cocoon system is further developed. In addition, the Lonza autologous cell therapy R&D group will maintain their complete support of Cocoon system-related activities from their Maryland R&D site.

(Source: Lonza Group Ltd.)

Related Articles Read More >

coronavirus COVID-19 Pfizer
7 core strategies in Biden’s battle against COVID-19
Biden’s COVID-19 response will make manufacturers busy
Catalent
Catalent to acquire Acorda’s manufacturing and packaging operations 
Halix
Halix to help make AstraZeneca’s COVID-19 vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards